HeartBeam Inc. Reports Q4 2025 and Full‑Year Results
HeartBeam Inc. (Nasdaq: BEAT) announced its financial results for the fourth quarter and full fiscal year 2025 on March 12, 2026. The company presented earnings data at a quarterly conference held on March 12 and subsequently provided detailed earnings call summaries throughout the following days.
Key Financial Highlights
| Metric | Q4 2025 | Full 2025 |
|---|---|---|
| Earnings per Share (EPS) | –$0.14 | –$0.620 |
| EPS (Year‑ago) | –$0.18 | –$0.730 |
The company noted that the quarterly loss per share improved from –$0.18 in the same period a year earlier. However, the loss for the full year remained substantial, at –$0.620 compared with –$0.730 previously.
Operational Context
HeartBeam’s business model focuses on telemedicine solutions for detecting and monitoring cardiac disease outside traditional healthcare settings. The firm reported that FDA clearances obtained in 2025 have paved the way for a commercial launch, potentially expanding market reach. Despite regulatory approvals, the company continues to navigate financial challenges as indicated by its negative price‑earnings ratio of –2.05 and a current share price of $1.36, below its 52‑week low of $0.54.
Market Position
The company’s market capitalization stands at approximately $54.6 million. Its global operations are headquartered in Santa Clara, United States, and the company serves customers worldwide through its website, www.heartbeam.com . While the recent earnings report shows continued losses, the regulatory milestones and the expansion of remote cardiac monitoring services suggest a strategic focus on long‑term growth.
Analyst Commentary
During the earnings call, executives highlighted progress in commercialization and clinical development. They acknowledged the need to strengthen financial performance while emphasizing the importance of FDA clearances and the impending commercial launch. Analysts noted the company’s ongoing efforts to reduce costs and drive revenue growth in a competitive telemedicine landscape.
